Loading...
Cart
0

Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agent/Diuretic, and Other Drugs) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_184602
Pages: 142
Apr 2018 | 1325 Views
 
Author(s) : Prateeksha Kaul and Pallavi Jaiswal
Tables: 63
Charts: 29
 

Aneurysmal Subarachnoid Hemorrhage Drugs Market Overview:

The global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023. Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke caused by bleeding in the space surrounding the brain. The major factors that drive the growth of the global aneurysmal subarachnoid hemorrhage drugs market include surge in geriatric population and high prevalence of population suffering from hypertension. Furthermore, lifestyle modifications such as alcohol consumption and smoking increase the risk of aSAH, which in turn propel the market growth. However, the associated side effects of drugs and medication taken during the treatment of aneurysmal subarachnoid hemorrhage restrain the market growth.

High incidence of hypertension

Hypertension is one of the major risk factors that can lead to aSAH. As per the Centers for Disease Control and Prevention, about 70 million American adults suffer from high blood pressure, of which the condition of only 52% is under control. Moreover, increase in the incidence of high blood pressure has cost the U.S. $46 billion annually, which include the cost of healthcare services, medications to treat high blood pressure, and missed days of work.
 

by geography

Get more information on this report : Request Sample Pages

Growth of geriatric population

According to a report published by the U.S. Census Bureau, the U.S. population is projected to grow from 314 million in 2012 to 400 million in 2050, showing an increase of 27%. Moreover, between 2012 and 2050, the U.S. is expected to witness considerable growth in its aging population. For instance, by 2050, the population aged 65 years and above is projected to reach 83.7 million, which is almost double its population of 43.1 million that was recorded in 2012. Thus, with increase in geriatric population, the incidence of disease such as hypertension, is projected to soar, which is expected to impact the aneurysmal subarachnoid hemorrhage drugs market proportionally.
 

by product

Get more information on this report : Request Sample Pages

The global aneurysmal subarachnoid hemorrhage drugs market is segmented based on drug class and region. Based on drug class, the market is segmented into opioid analgesic, calcium channel blocker, anticonvulsant, stool softener, osmotic agent/diuretic, and other drugs. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key companies operating in the market include Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.).

Key Benefits

  • The study provides an in-depth analysis of the global aneurysmal subarachnoid hemorrhage drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
  • Quantitative analysis from 2016 to 2023 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
  • An extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

Aneurysmal Subarachnoid Hemorrhage Drugs Market Key Segments:

By Drug Class

  • Opioid Analgesic
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agent
  • Other Drugs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2016
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rising geriatric population
3.4.1.2. Increasing prevalence of stroke and hypertension
3.4.1.3. Lifestyle modifications which increase the risk of aSAH

3.4.2. Restraints

3.4.2.1. Side effects of the drugs

3.4.3. Opportunities

3.4.3.1. Need for growing awareness about the treatment of aSAH

3.4.4. Impact analyses

CHAPTER 4: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Patients treated, by drug class
4.1.2. Market size and forecast

4.2. Opioid analgesics

4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast by region
4.2.3. Market analysis by country

4.3. Calcium channel blockers

4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast by region
4.3.3. Market analysis by country

4.4. Anticonvulsants

4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast by region
4.4.3. Market analysis by country

4.5. Stool softeners

4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast by region
4.5.3. Market analysis by country

4.6. Osmotic agents/diuretics

4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast by region
4.6.3. Market analysis by country

4.7. Other drugs

4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast by region
4.7.3. Market analysis by country

CHAPTER 5: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION

5.1. Overview

5.1.1. Market size and forecast

5.2. North America

5.2.1. Key market trends, growth factors & opportunities
5.2.2. Market size and forecast by country

5.2.2.1. U.S.

5.2.2.1.1. U.S. aneurysmal subarachnoid hemorrhage market, by drug class

5.2.2.2. Canada

5.2.2.2.1. Canada aneurysmal subarachnoid hemorrhage market, by drug class

5.2.2.3. Mexico

5.2.2.3.1. Mexico aneurysmal subarachnoid hemorrhage market, by drug class

5.2.3. North America market size and forecast by drug class

5.3. Europe

5.3.1. Key market trends, growth factors & opportunities
5.3.2. Market size and forecast by country

5.3.2.1. Germany

5.3.2.1.1. Germany aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.2. France

5.3.2.2.1. France aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.3. UK

5.3.2.3.1. UK aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.4. Italy

5.3.2.4.1. Italy aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.5. Spain

5.3.2.5.1. Spain aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.6. Rest of Europe

5.3.2.6.1. Rest of Europe aneurysmal subarachnoid hemorrhage market, by drug class

5.3.3. Europe market size and forecast by drug class

5.4. Asia-Pacific

5.4.1. Key market trends, growth factors & opportunities
5.4.2. Market size and forecast by country

5.4.2.1. Japan

5.4.2.1.1. Japan aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.2. China

5.4.2.2.1. China aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.3. Australia

5.4.2.3.1. Australia aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.4. India

5.4.2.4.1. India aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.5. South Korea

5.4.2.5.1. South Korea aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.6. Rest of Asia-Pacific

5.4.2.6.1. Rest of Asia-Pacific aneurysmal subarachnoid hemorrhage market, by drug class

5.4.3. Asia-Pacific market size and forecast by drug class

5.5. LAMEA

5.5.1. Key market trends, growth factors & opportunities
5.5.2. Market size and forecast by country

5.5.2.1. Brazil

5.5.2.1.1. Brazil aneurysmal subarachnoid hemorrhage market, by drug class

5.5.2.2. Saudi Arabia

5.5.2.2.1. Saudi Arabia aneurysmal subarachnoid hemorrhage market, by drug class

5.5.2.3. South Africa

5.5.2.3.1. South Africa aneurysmal subarachnoid hemorrhage market, by drug class

5.5.2.4. Rest of LAMEA

5.5.2.4.1. Rest of LAMEA aneurysmal subarachnoid hemorrhage market, by drug class

5.5.3. LAMEA market size and forecast by drug class

CHAPTER 6: COMPANY PROFILE

6.1. Arbor Pharmaceuticals Inc.

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Key strategic moves and developments

6.2. Edge Therapeutics, Inc.

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Product portfolio
6.2.4. Business performance

6.3. Johnson & Johnson (Actelion Pharmaceuticals Ltd.)

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance

6.4. Mylan N.V.

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance

6.5. Orexo AB

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Product portfolio
6.5.4. Business performance
6.5.5. Key strategic moves and developments

6.6. Pfizer Inc.

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.6.5. Business performance

6.7. Purdue Pharma L.P.

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Product portfolio
6.7.4. Key strategic moves and developments

6.8. Pharmaxis, Ltd.

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance

6.9. Sun Pharmaceutical Industries Ltd.

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product portfolio
6.9.5. Business performance

6.10. Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Business performance

LIST OF TABLES

TABLE 01. RISK FOR SUBARACHNOID HEMORRHAGE BASED ON SMOKING LEVEL
TABLE 02. PATIENTS TREATED, BY DRUG CLASS, 2015-2017
TABLE 03. GLOBAL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 04. OPIOID ANALGESICS MARKET, BY REGION, 2016-2023 ($THOUSAND)
TABLE 05. CALCIUM CHANNEL BLOCKERS MARKET, BY REGION, 2016-2023 ($THOUSAND)
TABLE 06. ANTICONVULSANTS MARKET, BY REGION, 2016-2023 ($THOUSAND)
TABLE 07. STOOL SOFTENERS MARKET, BY REGION, 2016-2023 ($THOUSAND)
TABLE 08. OSMOTIC AGENTS/DIURETICS MARKET, BY REGION, 2016-2023 ($THOUSAND)
TABLE 09. OTHER DRUGS MARKET, BY REGION, 2016-2023 ($THOUSAND)
TABLE 10. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION, 2016-2023 ($THOUSAND)
TABLE 11. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2016-2023 ($THOUSAND)
TABLE 12. U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 13. CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 14. MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 15. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 16. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2016-2023 ($THOUSAND)
TABLE 17. GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 18. FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 19. UK ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 20. ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 21. SPAIN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 22. REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 23. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 24. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2016-2023 ($THOUSAND)
TABLE 25. JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 26. CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 27. AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 28. INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 29. SOUTH KOREA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 30. REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 31. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 32. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2016-2023 ($THOUSAND)
TABLE 33. BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 34. SAUDI ARABIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 35. SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 36. REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 37. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)
TABLE 38. ARBOR: COMPANY SNAPSHOT
TABLE 39. ARBOR: PRODUCT SEGMENTS
TABLE 40. ARBOR: PRODUCT PORTFOLIO
TABLE 41. EDGE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 42. EDGE THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 43. J&J: COMPANY SNAPSHOT
TABLE 44. J&J: OPERATING SEGMENTS
TABLE 45. J&J: PRODUCT PORTFOLIO
TABLE 46. MYLAN: COMPANY SNAPSHOT
TABLE 47. MYLAN: OPERATING SEGMENTS
TABLE 48. MYLAN: PRODUCT PORTFOLIO
TABLE 49. OREXO: COMPANY SNAPSHOT
TABLE 50. OREXO: PRODUCT PORTFOLIO
TABLE 51. PFIZER: COMPANY SNAPSHOT
TABLE 52. PFIZER: OPERATING SEGMENTS
TABLE 53. PFIZER: PRODUCT PORTFOLIO
TABLE 54. PURDUE PHARMA: COMPANY SNAPSHOT
TABLE 55. PURDUE PHARMA: PRODUCT PORTFOLIO
TABLE 56. PHARMAXIS: COMPANY SNAPSHOT
TABLE 57. PHARMAXIS: OPERATING SEGMENTS
TABLE 58. PHARMAXIS: PRODUCT PORTFOLIO
TABLE 59. SUN PHARMA: COMPANY SNAPSHOT
TABLE 60. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 61. TEVA: COMPANY SNAPSHOT
TABLE 62. TEVA: OPERATING SEGMENTS
TABLE 63. TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING, 2016
FIGURE 04. IMPACT ANALYSES
FIGURE 05. COMPARATIVE ANALYSIS OF OPIOID ANALGESICS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)
FIGURE 06. COMPARATIVE ANALYSIS OF CALCIUM CHANNEL BLOCKERS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)
FIGURE 07. COMPARATIVE ANALYSIS OF ANTICONVULSANTS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)
FIGURE 08. COMPARATIVE ANALYSIS OF STOOL SOFTENERS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)
FIGURE 09. COMPARATIVE ANALYSIS OF OSMOTIC AGENTS/DIURETICS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)
FIGURE 10. COMPARATIVE ANALYSIS OF OTHER DRUGS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)
FIGURE 11. J&J: NET SALES, 2015-2017 ($MILLION)
FIGURE 12. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 13. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 14. MYLAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 15. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 16. OREXO: NET SALES, 2015-2017 ($MILLION)
FIGURE 17. OREXO: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 18. OREXO: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 19. PFIZER: NET SALES, 2015-2017 ($MILLION)
FIGURE 20. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 21. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 22. PHARMAXIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 23. PHARMAXIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 24. SUN PHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 25. SUN PHARMA: REVENUE SHARE BY BUSINESS UNITS, 2017 (%)
FIGURE 26. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. TEVA: NET SALES, 2015-2017 ($MILLION)
FIGURE 28. TEVA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 

 
 

Globally, diseases such as hypertension and stroke, constitute a major proportion of health and economic burden; hence, the development of effective medication is the major necessity for their treatment.

The major factors that contribute to the market growth include change in lifestyle and rise in geriatric population. In addition, lifestyle modifications, such as increased alcohol consumption and smoking, further increase the risk for aSAH, which stimulate the market growth. However, the associated side effects of the drugs are expected to restrain the market growth. In addition, a need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage provide lucrative opportunities for the market growth.

North America is estimated to dominate the aneurysmal subarachnoid hemorrhage drugs market throughout the forecast period, owing to increase in incidence of people suffering from hypertension, followed by Europe and Asia-Pacific.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Download Sample

Request Customization

Download Sample

OR

Purchase Full Report of
Aneurysmal Subarachnoid Hemorrhage Drugs Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • 20% free customization (Pre-Sale)
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
report-img

Published in  Jan 2015

Erythropoietin Drugs Market

Download Sample
report-img

Published in  Nov 2017

Protein Therapeutics Market

Download Sample
report-img

Published in  Mar 2018

Surgical Equipment Market

Download Sample
report-img

Published in  Aug 2016

Medical Implants Market

Download Sample
 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample

Buy Full Version
"Aneurysmal Subarachnoid Hemorrhage Drugs Market"
Purchase Enquiry